- Home
- GTI vs TLSI Comparison
GTI vs TLSI Comparison
Compare GTI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTI
- TLSI
- Stock Information
- Founded
- GTI 2019
- TLSI 2010
- Country
- GTI Malaysia
- TLSI United States
- Employees
- GTI N/A
- TLSI N/A
- Industry
- GTI
- TLSI Medical Specialities
- Sector
- GTI
- TLSI Health Care
- Exchange
- GTI NYSE
- TLSI Nasdaq
- Market Cap
- GTI 138.7M
- TLSI 124.9M
- IPO Year
- GTI N/A
- TLSI N/A
- Fundamental
- Price
- GTI $0.23
- TLSI $4.05
- Analyst Decision
- GTI
- TLSI Strong Buy
- Analyst Count
- GTI 0
- TLSI 6
- Target Price
- GTI N/A
- TLSI $11.75
- AVG Volume (30 Days)
- GTI 2.0M
- TLSI 54.4K
- Earning Date
- GTI 12-31-2024
- TLSI 11-14-2024
- Dividend Yield
- GTI N/A
- TLSI N/A
- EPS Growth
- GTI N/A
- TLSI N/A
- EPS
- GTI N/A
- TLSI N/A
- Revenue
- GTI N/A
- TLSI $26,891,000.00
- Revenue This Year
- GTI N/A
- TLSI $60.97
- Revenue Next Year
- GTI N/A
- TLSI $53.69
- P/E Ratio
- GTI N/A
- TLSI N/A
- Revenue Growth
- GTI N/A
- TLSI 67.90
- 52 Week Low
- GTI $0.19
- TLSI $3.50
- 52 Week High
- GTI $14.00
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- GTI 22.54
- TLSI 49.84
- Support Level
- GTI $0.82
- TLSI $3.60
- Resistance Level
- GTI $1.50
- TLSI $4.17
- Average True Range (ATR)
- GTI 0.52
- TLSI 0.37
- MACD
- GTI -0.22
- TLSI -0.03
- Stochastic Oscillator
- GTI 1.34
- TLSI 42.31
About GTI GRAPHJET TECHNOLOGY
Graphjet Technology is a company that owns state-of-the-art technology for the manufacture of artificial graphene and graphite, critical raw materials used in a variety of industries. The technology was developed through our collaboration with National University of Malaysia and Universiti Teknikal Malaysia Melaka. It produces artificial graphite and graphene from palm seed kernels, a waste product widely available in Malaysia and other countries that produce palm seed oil. Unlike mineral coal-based or petroleum-based graphite which is ultimately limited and must be mined and processed to produce commercial-grade graphite, our raw materials are renewable and effectively unlimited.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.